2026，全球暢銷藥Top10(預測版)

賽柏藍

02/19

編者按：本文來自米內網，作者皓月；賽柏藍授權轉載，編輯相宜2025年年末，權威雜誌《Nature Reviews Drug Discovery》發布了一份商業分析簡訊：Top product forecasts for 2026。在簡訊中，Evaluate Pharma分析師對2026年全球十大暢銷藥品的銷售額、排名變動做出專業預測，揭開了未來醫藥市場的競爭走向。01近$2000億TOP10排行榜...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612236099"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612236099\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612236099?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-19 17:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2612236099","market":"us","top_or_hot":-1,"title":"2026，全球暢銷藥Top10(預測版)","media":"賽柏藍","content":"<div>\n<p>編者按：本文來自米內網，作者皓月；賽柏藍授權轉載，編輯相宜2025年年末，權威雜誌《Nature Reviews Drug Discovery》發布了一份商業分析簡訊：Top product forecasts for 2026。在簡訊中，Evaluate Pharma分析師對2026年全球十大暢銷藥品的銷售額、排名變動做出專業預測，揭開了未來醫藥市場的競爭走向。01近$2000億TOP10排行榜...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2026，全球暢銷藥Top10(預測版)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2026，全球暢銷藥Top10(預測版)\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">賽柏藍</strong><span class=\"h-time small\">2026-02-19 17:02</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>編者按：本文來自米內網，作者皓月；賽柏藍授權轉載，編輯相宜2025年年末，權威雜誌《Nature Reviews Drug Discovery》發布了一份商業分析簡訊：Top product forecasts for 2026。在簡訊中，Evaluate Pharma分析師對2026年全球十大暢銷藥品的銷售額、排名變動做出專業預測，揭開了未來醫藥市場的競爭走向。01近$2000億TOP10排行榜...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b\">賽柏藍</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089984988.USD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b","article_id":"2612236099","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612236099","pubTimestamp":1771491774,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"在簡訊中，Evaluate Pharma分析師對2026年全球十大暢銷藥品的銷售額、排名變動做出專業預測，揭開了未來醫藥市場的競爭走向。與上一年的預測相比，2026年全球TOP10暢銷藥品的產品陣容保持不變，但整體銷售額有明顯的攀升，預計TOP10產品總銷售額將接近兩千億美元關口，按年增長達到18%。Eliquis在2026年預計銷售額將達121億美元，但這個極大可能是Eliquis最後一次入選TOP10暢銷藥排行榜。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","BK4007":"制药","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LLY":"礼来","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0861579265.USD":"联博低波幅策略股票基金A","BK4532":"文艺复兴科技持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","MRK":"默沙东","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4534":"瑞士信贷持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999001176.USD":"United Global Healthcare Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4516":"特朗普概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","NVOX":"2倍做多NVO ETF-Defiance","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","SG9999002232.USD":"Allianz Global High Payout USD","BK4559":"巴菲特持仓","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4550":"红杉资本持仓","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","BK4588":"碎股","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","NVO":"诺和诺德","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4599":"减肥药","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC"},"translate_title":"2026, Top 10 best-selling drugs in the world (forecast version)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1.88,"NVO":1.9,"NVOH":0.6,"LLY":1.92,"NVOX":0.6},"content_text":"編者按：本文來自米內網，作者皓月；賽柏藍授權轉載，編輯相宜2025年年末，權威雜誌《Nature Reviews Drug Discovery》發布了一份商業分析簡訊：Top product forecasts for 2026。在簡訊中，Evaluate Pharma分析師對2026年全球十大暢銷藥品的銷售額、排名變動做出專業預測，揭開了未來醫藥市場的競爭走向。01近$2000億TOP10排行榜揭曉$338億「藥王」蟬聯榜首2026年TOP10暢銷藥品預測2026年，默沙東的PD-1單抗Keytruda（帕博利珠單抗）攜手其皮下注射製劑Qlex依舊蟬聯全球暢銷藥榜首，預計銷售額達338億美元。禮來的GLP-1R/GIPR雙重激動劑Mounjaro（替爾泊肽）憑藉258億美元的銷售額緊跟其後。艾伯維的IL-23單抗Skyrizi（利生奇珠單抗）位列第三。與上一年的預測相比，2026年全球TOP10暢銷藥品的產品陣容保持不變，但整體銷售額有明顯的攀升，預計TOP10產品總銷售額將接近兩千億美元關口，按年增長達到18%。與此同時，排行榜內的排名進行了明顯的「洗牌」，其中GLP-1賽道的替爾泊肽和司美格魯肽排名的反向變化成為本次排行榜調整的核心看點，也是推動排行榜格局重塑的關鍵因素。02替爾泊肽一路高漲實現反超GLP-1「雙雄」走勢分化根據預測，禮來降糖版替爾泊肽（Mounjaro）以258億美元的預測銷售額，牢牢佔據排行榜第二的位置。其減重版本Zepbound更是一路高歌，排名狂升5位，成功闖入排行榜前五。老對手諾和諾德核心產品司美格魯肽市場表現承壓。降糖藥Ozempic（司美格魯肽注射液）銷售額預測縮水，從2025年的222.5億美元降至2026年的197億美元，排名直接從第二滑落至第六。另一款司美格魯肽減肥注射液（Wegovy），最終排在排行榜第八位，GLP-1「雙雄」的走勢徹底分化。禮來的領先優勢，在2025年已正式確立。2025年一季度末，禮來公開宣佈，其已拿下美國腸促胰島素類似物市場的領導地位，以53.3%的處方量佔比，首次超越諾和諾德。面對禮來的強勢狙擊，諾和諾德在2025年四次下調全年銷售增長預期，將最初16%-24%的增長區間，收窄至8%-11%。業績指引的持續下調，直觀反映出公司對GLP-1糖尿病與肥胖症療法增長前景的謹慎預期。財報數據進一步印證了這一格局轉變。進入2025年後，諾和諾德的3款司美格魯肽單季合計銷售額始終未能突破2024年第四季度的606億丹麥克朗（約87億美元）的峯值。而禮來兩款替爾泊肽產品合計銷售額在2025年第二季度便達到85.8億美元，實現對司美格魯肽的反超。2025年第三季度，替爾泊肽雙產品合計銷售額更是突破100億美元大關，達到101.03億美元，增長勢頭遠超競品。2022-2025Q3司美格魯肽和替爾泊肽的銷售對比GLP-1類藥物的市場潛力正以肉眼可見的速度高速釋放，全球千億級市場規模持續擴容。當前，諾和諾德與禮來形成的「雙巨頭」競爭格局雖暫時穩固，但並非鐵板一塊，各類迭代在研產品噴湧而出，有望成為攪動全球GLP-1賽道競爭的新力量。Evaluate Pharma在另一份專項報告中明確預測，2026年全球最具潛力的待上市藥物及生物製藥領域高價值研發項目中，GLP-1相關藥物均佔據核心地位。行業內有觀點認為，胰澱素療法有望取代GLP-1機制，成為肥胖症和2型糖尿病的核心代謝治療方案。諾和諾德將研發重心放在GLP-1類藥物與胰澱素（Amylin）類藥物的聯合應用探索上，試圖憑藉機制創新尋找翻盤契機。其中，其研發的胰澱素與GLP-1激動劑固定劑量複方製劑CagriSema位居2026年最具潛力上市藥物榜首，並且該藥已於2025年底提交了上市申請。諾和諾德另一款與胰澱素相關的明星產品Amyeretin目前正式啓動Ⅲ期臨床試驗。與之對應，禮來則聚焦小分子口服劑型與多靶點機制藥物研發。其研發的口服GLP-1激動劑Orforglipron也已提交了上市申請，專門對標諾和諾德已上市口服司美格魯肽Rybelsus。同時，在GLP-1三靶點激動劑賽道，禮來的Retatrutide研發進展全球最快，目前正同步開展肥胖、2型糖尿病、心血管事件二級預防、阻塞型睡眠呼吸暫停等多項適應症的Ⅲ期臨床試驗。2026年最具潛力的待上市藥物生物製藥領域高價值研發項目034款重磅藥遇「專利懸崖」11款司美格魯肽蓄勢待發百億銷售額的光環之下，2026年全球TOP10暢銷藥正遭遇「專利懸崖」的致命考驗。這場席捲全球醫藥行業的專利到期潮，成為各大藥企無法迴避的生存挑戰。在這份排行榜中，Eliquis（阿哌沙班）、Ozempic（司美格魯肽）、Keytruda（帕博利珠單抗）、Darzalex（達雷妥尤單抗）四款TOP10成員將在未來五年內陸續迎來「專利懸崖」，其市場獨佔權喪失後，銷售額恐面臨斷崖式縮水，進而重塑全球醫藥市場頭部格局。TOP10暢銷藥品近年專利到期情況最受關注的是「藥王」Keytruda，這款PD-1抑制劑在2024年實現約294.8億美元的全球銷售，佔默沙東總收入接近一半。Keytruda將在2028年前後於美國等關鍵市場面臨生物類似藥競爭。即便默沙東已提前推進皮下注射劑型，試圖延長商業生命周期，這一時間點仍然意味着一個確定的拐點：一旦生物類似藥進入，價格與市場份額都會迅速承壓。阿哌沙班（Eliquis）的專利壓力更為緊迫，這款由BMS與輝瑞聯合商業化的口服抗凝藥，核心化合物專利將於2026年到期。BMS在投資者溝通中已明確提示，2026–2027年將進入專利影響逐步顯現的階段。Eliquis在2026年預計銷售額將達121億美元，但這個極大可能是Eliquis最後一次入選TOP10暢銷藥排行榜。諾和諾德Ozempic在中國的專利也將於今年到期，仿製藥的進入加劇了這款GLP-1激動劑的銷售下行壓力。數據顯示，2025年前三季度司美格魯肽注射液在中國三大終端六大市場銷售額接近60億元，諾和諾德獨攬市場。目前，國內已有11款司美格魯肽生物類似藥的上市申請獲受理，包括正大天晴藥業、石藥集團、復星萬邦等，另有多家企業已進入Ⅲ期臨床，市場競爭漸趨白熱化。近年來中國三大終端六大市場司美格魯肽注射液銷售情況（單位：萬元）強生的「銷冠」達雷妥尤單抗（Darzalex）也無法繞過專利懸崖。靶向CD38的Darzalex作為治療多發性骨髓瘤的核心藥物，2023年該藥全球銷售額超過97億美元，後續則持續強勢上漲，2024年首次突破「百億大關」達到116.7億美元。強生正通過持續拓展適應症鞏固市場，2024年先後提交新診斷不適合幹細胞移植的多發性骨髓瘤、高風險冒煙型多發性骨髓瘤兩項適應症申請，試圖延緩專利到期後的銷售額下滑態勢，但長期仍難抵生物類似藥的衝擊。2026年全球TOP10暢銷藥預測榜，藏着醫藥行業的「不變與劇變」——產品陣容未改，核心格局卻已然重塑，「危」與「機」雙向交織。排行榜排名的大洗牌，直白道出市場熱點的轉移：以GLP-1為代表的代謝藥物強勢崛起，有望改寫全球醫藥市場的價值格局、登頂行業巔峯。更關鍵的是，未來五年，「專利到期潮」洶湧來襲，將狠狠衝擊多家頂級藥企，這場行業大洗牌，已然箭在弦上。資料來源：Evaluate Pharma、企業財報、米內網數據庫等","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}